Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWO85H)

Drug Name

TMPyP4 Drug Info

Synonyms

TMPP; AC1L1HPJ; N-Methylpyridylylporphyrin; AC1Q29RK; CHEMBL65606; ABCGFHPGHXSVKI-UHFFFAOYSA-O; BDBM50107609; 4,4',4'',4'''-(5,10,15,20-porphyrintetrayl)tetrakis(1-methylpyridinium); J2.096.016G; 5,10,15,20-tetra(1-methyl-4-pyridyl)-porphyrin; 5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,22-dihydroporphyrin

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Investigative	[1]

Cross-matching ID

PubChem CID: 135398505
CAS Number: CAS 38673-65-3
TTD Drug ID: DMWO85H

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Telomerase reverse transcriptase (TERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Berberine	DMC5Q8X	N. A.	N. A.	Phase 4	[2]
GV1001	DMHULRK	Pancreatic cancer	2C10	Phase 3	[3]
Imetelstat	DMONWJ4	Myelodysplastic syndrome	2A37	Phase 2/3	[4]
VM1500A	DM9YSSY	Human immunodeficiency virus-1 infection	1C62	Phase 2/3	[5]
Dendritic cell vaccine	DML4PMG	Ovarian cancer	2C73	Phase 2	[6]
GRNVAC1	DMAHOEP	Acute myeloid leukaemia	2A60	Phase 2	[7]
Vx-001	DMDKWA3	Breast cancer	2C60-2C65	Phase 2	[8]
CB-10-01	DM2IFYZ	Melanoma	2C30	Phase 2	[9]
Epithalon	DMWSGZU	Ocular inflammation	9C61.24	Phase 1/2	[10]
OBP-301	DM9MF08	Breast cancer	2C60-2C65	Phase 1/2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Telomerase reverse transcriptase (TERT)	TTUJFD0	TERT_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
2	Stage specificity of Plasmodium falciparum telomerase and its inhibition by berberine. Parasitol Int. 2002 Mar;51(1):99-103.
3	Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer. 2006 Dec 4;95(11):1474-82.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Biochemical profiling of anti-HIV prodrug Elsulfavirine (Elpida(?)) and its active form VM1500A against a panel of twelve human carbonic anhydrase isoforms. J Enzyme Inhib Med Chem. 2021 Dec;36(1):1056-1060.
6	In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells. J Immunotoxicol. 2009 Dec;6(4):243-8.
7	Targeting telomerase-expressing cancer cells. J Cell Mol Med. 2011 Jul;15(7):1433-42.
8	Clinical pipeline report, company report or official report of Vaxon-biotech.
9	Telomerase immunity from bench to bedside: round one. J Transl Med. 2007 Feb 26;5:12.
10	Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003 Jun;135(6):590-2.
11	Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):285-92.